Basic information Biological Activity In vitro studies In vivo studies Safety Related Supplier
ChemicalBook >  Product Catalog >  Biochemical Engineering >  Inhibitors >  protein tyrosine kinase >  WZ4002

WZ4002

Basic information Biological Activity In vitro studies In vivo studies Safety Related Supplier
WZ4002 Basic information
WZ4002 Chemical Properties
  • Density 1.314
  • pka12.78±0.70(Predicted)
WZ4002 Usage And Synthesis
  • Biological ActivityWZ4002 is a novel, mutant selective EGFR inhibitor. The IC50 is 2 nM/8 nM when it acts on IC50 of 2 nM/8 nM in EGFR (L858R)/(T790M), and it has no inhibitory effect on ERBB2 phosphorylation (T798I).
  • In vitro studiesWZ4002 also inhibit other EGFR genotypes. For instance, the IC50 is 2nM and 6nM respectively when it acts on E746_A750 and E746_A750/T790M. Besides, the IC50 is 32nM when it acts on wild-type EGFR. It could inhibit the phosphorylation of EGFR, AKT and ERK1/2 when it acts on non-small cell lung cancer (NSCLC). WZ4002 also could inhibit the phosphorylation of EGFR when it acts on NIH-3T3 cells expressing different EGFRT790M mutant alleles. The dissociation constant of kinase was 95% higher when in the test when WZ4002 involved than that in the test DMSO involved instead. Because in aniline substitution in the C2 WZ4002 could obtain a methoxy group when it acts on EGFR, thus it’s more effective when it acts on EGFR than WZ3146. Compared with the quinazoline inhibitors, the efficiency of WZ4002 is 100 times lower than when it acts on wild-type EGFR. The inhibitory effect of WZ4002 on EGFR kinase activity of recombinant L858R/T790M protein is much higher than restrainable wild-type EGFR’s. However HKI-272 and Gefitinib are happened to have opposite inhibitory effect compared with WZ4002. In addition, phosphorylation of EGFR in H1975 and HCC827 cells of anti-Src TKI could be completely inhibited by third-generation EGFR TKI and WZ4002.
  • In vivo studiesWhen treated with T790M mutant mouse model for 2 weeks and had been used to study the efficacy of WZ4002, it is found that treatment with WZ4002 resulted in more effective significant tumor regression compared to the control group. When treated with low dose WZ4002 and high dose WZ4002, it would resulted in a 26% and 36% decrease in average uptake respectively.
  • UsesA novel mutant-selective EGFR kinase inhibitor of EGFRL858R and EGFRL858R/T790M with IC50s of 2 nM and 8 nM, respectively.
WZ4002(1213269-23-8)Related Product Information
WZ4002SupplierMore
  • Company Name:Nanjing Gold Pharmaceutical Technology Co. Ltd. Gold
  • Tel:15905158493
  • Email:wgp@nanjing-pharmaceutical.com;wgp@nanjing-pharmaceutical.com
  • Products Intro:Product Name:WZ4002
    CAS:1213269-23-8
    Purity:99% Package:1G 1KG 100KG
  •  
  • Company Name:Wuhan Chemprospect Pharmaceutical Co., Ltd. Gold
  • Tel:13971349987 027-84454860-
  • Email:sale@chemprospect.com
  • Products Intro:Product Name:WZ4002 HBr
    Purity:>99% Package:1g/bag, 10g/bag, 1kg/bag...
  •  
  • Company Name:Shanghai Valuable Catalysts Pharmaceutical Co. Ltd Gold
  • Tel:13331882176
  • Email:2253973700@qq.com
  • Products Intro:Product Name:WZ4002
    CAS:1213269-23-8
    Purity:96%,NMR Package:1g
  •  
  • Company Name:Zhongxin Chenshi (Wuhan) Technology Co., Ltd Gold
  • Tel:18942922096 027-1894292-2096
  • Email:2662561040@qq.com
  • Products Intro:Product Name:WZ-4002
    CAS:1213269-23-8
    Purity:0.99 Package:500克 Remarks:500g
  •  
  • Company Name:Shanghai Boyle Chemical Co., Ltd.
  • Tel:
  • Email:sales@boylechem.com
  • Products Intro:Product Name:WZ4002
    CAS:1213269-23-8
  •